Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Post stroke headache occurs in approximately 10-23% of all stroke patients. Its onset is
shortly after experiencing a stroke, or stroke like event, and persists for at least three
months. These headaches have features which resemble migraine or occur in people who have a
previous history of migraine that was once infrequent. Botox is a treatment that is currently
approved for the treatment of chronic migraine, that is migraine headaches occurring for at
least 15 days a month for at least 3 months. Given the clinical similarity in character and
frequency of post stroke headache and migraine, and the fact that stroke affects structures
like the blood vessels in the brain that are also affected in migraine, this study is to
investigate the possible role that Botox would have in the treatment of Post-Stroke Headache.